Van ECK Associates Corp Sells 119,848 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Van ECK Associates Corp lessened its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC) by 34.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 223,420 shares of the company’s stock after selling 119,848 shares during the quarter. Van ECK Associates Corp owned about 0.06% of Bausch Health Companies worth $1,801,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. CIBC Asset Management Inc lifted its position in Bausch Health Companies by 0.3% in the 3rd quarter. CIBC Asset Management Inc now owns 374,729 shares of the company’s stock worth $3,060,000 after buying an additional 1,082 shares during the last quarter. Tobam lifted its position in Bausch Health Companies by 10.4% in the 4th quarter. Tobam now owns 15,034 shares of the company’s stock worth $121,000 after buying an additional 1,422 shares during the last quarter. Northwest & Ethical Investments L.P. lifted its position in Bausch Health Companies by 13.0% in the 3rd quarter. Northwest & Ethical Investments L.P. now owns 32,384 shares of the company’s stock worth $264,000 after buying an additional 3,734 shares during the last quarter. Sanders Morris Harris LLC lifted its position in Bausch Health Companies by 16.0% in the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock worth $234,000 after buying an additional 4,000 shares during the last quarter. Finally, Creative Planning lifted its position in Bausch Health Companies by 16.9% in the 3rd quarter. Creative Planning now owns 55,351 shares of the company’s stock worth $452,000 after buying an additional 7,995 shares during the last quarter. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Trading Up 1.7 %

NYSE BHC opened at $7.31 on Friday. The stock has a market cap of $2.64 billion, a P/E ratio of -60.87, a P/E/G ratio of 0.34 and a beta of 0.68. Bausch Health Companies Inc. has a 12 month low of $3.96 and a 12 month high of $11.46. The stock’s fifty day moving average price is $7.35 and its 200-day moving average price is $7.48.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). The business had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 650.39%. As a group, analysts forecast that Bausch Health Companies Inc. will post 4.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Jefferies Financial Group restated a “hold” rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. Finally, Royal Bank of Canada dropped their target price on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $7.42.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.